Parents' dilemma: A therapeutic decision for children with spinal muscular atrophy (SMA) type 1

Sophie Boursange1,2,3, Marco Araneda4, Caroline Stalens5

  • 1Université Paris Cité, Laboratoire de Psychologie Clinique, Psychopathologie, Psychanalyse, Boulogne-Billancourt, France.

Frontiers in Pediatrics
|January 9, 2023
PubMed

Insights

Parents of children with SMA type 1 faced difficult decisions regarding innovative therapies. While most felt involved, non-hesitant parents experienced more depression and anxiety, highlighting the complex psychological impact of these life-saving treatments.

Area of Science:

  • Pediatric Neurology
  • Genetics
  • Psychology

Background:

  • Spinal Muscular Atrophy (SMA) type 1 is a severe, life-limiting neurodegenerative disorder.
  • Innovative therapies offer increased life expectancy for children with SMA type 1.
  • Understanding parental experiences with treatment decisions is crucial.

Purpose of the Study:

  • To explore parents' experiences with deciding on innovative therapies for SMA type 1.
  • To assess the medium-term psychological effects on parents.
  • To compare experiences between hesitant and non-hesitant parents, and those receiving gene therapy versus other innovative treatments.

Main Methods:

  • In-depth interviews, self-administered questionnaires, and validated psychological scales (BDI-II, STAI-Y, PSI-SF, SOC-13, PBA, DAS 16, FICD).
  • Comparison between parents who hesitated versus those who did not.
  • Comparison between parents whose children received gene therapy (GT) versus other innovative therapies.

Main Results:

  • Most parents felt involved in decision-making and satisfied with treatment outcomes.
  • Non-hesitant parents reported higher depression (p<0.001), anxiety (p=0.022), and parental stress (p=0.026) than hesitant parents.
  • Parents receiving GT reported higher depression (p=0.036) than those receiving other therapies.
  • Qualitative data revealed a strong desire to save the child's life, fear of end-of-life care, trust in physicians, and hope for the child's future.

Conclusions:

  • Hesitation before treatment decisions did not predict higher depression or anxiety.
  • Parents faced significant dilemmas in urgent situations, with ongoing reflection throughout the care process.
  • The decision-making process for innovative SMA therapies is complex and emotionally taxing for parents.
Abstract

Related Concept Videos

Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
540
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.2K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
210